Eisai Opens Regional Office in Bahrain
Eisai started doing business with the Middle East in the 1960’s. It has since focused on the sale of products imported from Japan and up until now has been using local distributors to deliver these in-house developed pharmaceuticals and other products to patients.
This year Eisai launched Methycobal®, a treatment for peripheral neuropathy, in Saudi Arabia, the biggest market in the Middle East, and the United Arab Emirates, and from next year it also hopes to receive approval to market other new products. With this in mind, Eisai has been moving forward with preparations for the opening of the Bahrain Regional Office in order to establish an operational base in the area, as it looks towards full-scale business expansion in the Middle East and North Africa in the future. Eisai will commence operations in the region primarily through working with local distributors, while taking responsibility for marketing and registration of pharmaceutical products.
Eisai currently operates globally in the United States, Europe and Asia. The Company sees the opening of the Bahrain Regional Office as an opportunity to make its in-house products available continuously as well as to actively introduce licensed products, which match the needs of the Middle East and North Africa, thereby contributing to addressing the needs and increasing the benefits of patients and their families in the region.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.